Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Hutchison China Ads (HCM)

Hutchison China Ads (HCM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,549,786
  • Shares Outstanding, K 133,357
  • Annual Sales, $ 214,110 K
  • Annual Income, $ -74,800 K
  • 60-Month Beta 0.64
  • Price/Sales 12.30
  • Price/Cash Flow N/A
  • Price/Book 7.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.47 +16.09%
on 09/30/19
21.36 -10.49%
on 09/19/19
-1.62 (-7.81%)
since 09/18/19
3-Month
16.47 +16.09%
on 09/30/19
22.34 -14.41%
on 09/13/19
-2.10 (-9.90%)
since 07/18/19
52-Week
16.47 +16.09%
on 09/30/19
39.68 -51.81%
on 11/14/18
-10.85 (-36.20%)
since 10/18/18

Most Recent Stories

More News
Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent eValuation In gastric cancer basKeT KORea studY) trial...

HCM : 19.12 (-3.19%)
Edison issues ADR update on Hutchison China MediTech (HCM)

LONDON, UK / ACCESSWIRE / October 10, 2019 / Hutchison China MediTech (NASDAQ:HCM) presented robust SANET-ep Phase III China data at ESMO 2019 on surufatinib in non-pancreatic neuroendocrine tumors (NET)....

CKHUF : 9.2500 (-1.09%)
HCM : 19.12 (-3.19%)
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) and Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration agreement to evaluate...

HCM : 19.12 (-3.19%)
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase ("Syk") inhibitor, in patients with relapsed...

HCM : 19.12 (-3.19%)
CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

CKHUF : 9.2500 (-1.09%)
HCM : 19.12 (-3.19%)
Hutchison China MediTech Solutions Enters Oversold Territory

Hutchison China MediTech has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

HCM : 19.12 (-3.19%)
CK Hutchison offers 1.3% of Chi-Med's share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

CKHUF : 9.2500 (-1.09%)
HCM : 19.12 (-3.19%)
Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

- Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors ("NET") to be presented -

HCM : 19.12 (-3.19%)
Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22 Annual Meeting of the...

HCM : 19.12 (-3.19%)
Top Ranked Momentum Stocks to Buy for September 16th

Top Ranked Momentum Stocks to Buy for September 16th

WBK : 19.79 (+0.25%)
LOB : 18.02 (-0.22%)
HCM : 19.12 (-3.19%)
CVS : 66.16 (-0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade HCM with:

Business Summary

Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong.

See More

Key Turning Points

2nd Resistance Point 20.33
1st Resistance Point 19.73
Last Price 19.12
1st Support Level 18.59
2nd Support Level 18.05

See More

52-Week High 39.68
Fibonacci 61.8% 30.81
Fibonacci 50% 28.08
Fibonacci 38.2% 25.34
Last Price 19.12
52-Week Low 16.47

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar